Guillain-Barré syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma

J Peripher Nerv Syst. 2007 Jun;12(2):142-3. doi: 10.1111/j.1529-8027.2007.00134.x.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Cyclophosphamide / adverse effects
  • Doxorubicin / adverse effects
  • Guillain-Barre Syndrome / chemically induced*
  • Guillain-Barre Syndrome / physiopathology*
  • Guillain-Barre Syndrome / therapy
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Lymphoma, Non-Hodgkin / drug therapy
  • Male
  • Methylprednisolone / therapeutic use
  • Plasma Exchange
  • Prednisone / adverse effects
  • Rituximab
  • Vincristine / adverse effects

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Immunoglobulins, Intravenous
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone
  • Methylprednisolone

Supplementary concepts

  • CHOP protocol